Results

Total Results: 76 records

Showing results for "venous thromboembolism".
Users also searched for: vte

1. Archived: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/v2-menopausal-hormone-therapy-preventive-medicatio
   May 09, 2005 - Harms include increased risk for venous thromboembolism (fair evidence), stroke (fair evidence), dementia … Other harms include increased risk for breast cancer (good evidence), venous thromboembolism (good evidence … For example, for combined estrogen and progestin, some risks (such as the risks for venous thromboembolism … The estrogen-only arm of the WHI trial showed a trend toward increased risk for venous thromboembolism … Hormone Replacement Therapy and Risk of Venous Thromboembolism .

2. Archived: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication-2002-2005
   May 09, 2005 - Harms include increased risk for venous thromboembolism (fair evidence), stroke (fair evidence), dementia … Other harms include increased risk for breast cancer (good evidence), venous thromboembolism (good evidence … For example, for combined estrogen and progestin, some risks (such as the risks for venous thromboembolism … The estrogen-only arm of the WHI trial showed a trend toward increased risk for venous thromboembolism … Hormone Replacement Therapy and Risk of Venous Thromboembolism .

3. Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendation Statement (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/s9NcVWwGErrH9b9M_6NryW
   May 01, 2005 - Other harms include increased risk for breast cancer (good evidence), venous thromboembolism (good evidence … Harms include increased risk for venous thromboembolism (fair evidence), stroke (fair evidence), dementia … The estrogen-only arm of the WHI trial showed a trend toward increased risk for venous thromboembolism … Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and … Hormone Replacement Therapy and Risk of Venous Thromboembolism.

4. Postmenopausal Hormone Replacement Therapy for the Primary Prevention of Chronic Conditions: A Summary of the Evidence for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/sQ7hREGwnBm8Wh-LEFWP4F
   October 01, 2002 - Potential benefits of Hormone Replacement Therapy Analytic Framework 1 Venous thromboembolism (DVT/PE … Venous thromboembolism (deep vein thrombosis and pulmonary embolism)? 2. Breast cancer incidence? … Venous thromboembolism? … Hormone Replacement Therapy and Risk of Venous Thromboembolism. … Risk of venous thromboembolism in users of hormone replacement therapy.

5. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/v1-breast-cancer-medications-for-risk-reduction--s
   July 08, 2002 - incidence between the tamoxifen and placebo groups in this age group. 7 The relative risk increase in venous … thromboembolism from tamoxifen or raloxifene appears similar to the risk for venous thromboembolism

6. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2002
   July 08, 2002 - incidence between the tamoxifen and placebo groups in this age group. 7 The relative risk increase in venous … thromboembolism from tamoxifen or raloxifene appears similar to the risk for venous thromboembolism

7. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/v2-menopausal-hormone-therapy-preventive-medicatio
   August 21, 2002 - Although our review supports an association between HRT and increased risk for venous thromboembolism … Hormone Replacement Therapy and Risk of Venous Thromboembolism . … Hormone replacement therapy and risk of venous thromboembolism: a systematic review and meta-analysis … Risk of venous thromboembolism in users of hormone replacement therapy. … Venous thromboembolism?

8. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/menopausal-hormone-therapy-preventive-medication-2002-2005
   August 21, 2002 - Although our review supports an association between HRT and increased risk for venous thromboembolism … Hormone Replacement Therapy and Risk of Venous Thromboembolism . … Hormone replacement therapy and risk of venous thromboembolism: a systematic review and meta-analysis … Risk of venous thromboembolism in users of hormone replacement therapy. … Venous thromboembolism?

9. Chemoprevention of Breast Cancer - Recommendations and Rationale (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/MnkNvteY4Yg_8Jut4SayVN
   July 02, 2002 - incidence between the tamoxifen and placebo groups in this age group.7 The relative risk increase in venous … thromboembolism from tamoxifen or raloxifene appears similar to the risk for venous thromboembolism

10. Archived: Final Evidence Summary: Menopausal Hormone Therapy: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary36/menopausal-hormone-therapy-preventive-medication-2012
    May 29, 2012 - Potential harms include coronary heart disease events; stroke; cognitive decline; venous thromboembolism … Potential harms include coronary heart disease events; stroke; cognitive decline; venous thromboembolism

11. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the USPSTF Recommendations (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/G7CCbu64mf-nCynBkHbFLA
    July 01, 2012 - Potential harms include coronary heart disease events; stroke; cognitive decline; venous thromboembolism

12. Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication
    December 12, 2017 - thromboembolism (11 more cases [95% CI, 3 to 22]), and urinary incontinence (1261 more cases [95% CI … thromboembolism (21 more cases [95% CI, 12 to 33]). … thromboembolism ( Table 3 and Figure 3 ; Table 4 summarizes the strength of evidence). … thromboembolism (21 more cases per 10,000 patient-years [95% CI, 12 to 33]) were also statistically … Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the

13. Archived: Evidence Summary: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/menopausal-hormone-therapy-preventive-medication-december-2017
    December 12, 2017 - thromboembolism (11 more cases [95% CI, 3 to 22]), and urinary incontinence (1261 more cases [95% CI … thromboembolism (21 more cases [95% CI, 12 to 33]). … thromboembolism ( Table 3 and Figure 3 ; Table 4 summarizes the strength of evidence). … thromboembolism (21 more cases per 10,000 patient-years [95% CI, 12 to 33]) were also statistically … Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the

14. Draft Recommendation: Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/menopausal-hormone-therapy-postmenopausal-persons-primary-prevention-chronic-conditions
    April 19, 2022 - progestin is associated with moderate harms, including increased risk of invasive breast cancer, stroke, venous … thromboembolism, dementia, gallbladder disease, and urinary incontinence.  … evidence that use of estrogen alone is associated with moderate harms, including increased risk of stroke, venous … thromboembolism, gallbladder disease, and urinary incontinence.

15. Draft Research Plan: Hypertensive Disorders of Pregnancy: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/draft-research-plan/hypertensive-disorders-pregnancy-screening
    May 20, 2021 - infarction Renal or hepatic injury/failure Pulmonary edema, adult respiratory distress syndrome Venous … thromboembolism (deep vein thrombosis/pulmonary embolism) Disseminated intravascular coagulation

16. Final Research Plan: Hypertensive Disorders of Pregnancy: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/hypertensive-disorders-pregnancy-screening
    September 02, 2021 - infarction Renal or hepatic injury/failure Pulmonary edema, adult respiratory distress syndrome Venous … thromboembolism (deep vein thrombosis/pulmonary embolism) Disseminated intravascular coagulation

17. Archived: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication-december-2017
    December 12, 2017 - thromboembolism, and a small to moderate harm of increased risk of coronary heart disease. … thromboembolism. … thromboembolism between women randomized to hormone therapy vs placebo over 2 to 3 years; however, the … thromboembolism b 21 (12 to 33) Urinary incontinence 876 (606 to 1168) Benefits … thromboembolism b 11 (3 to 22) Urinary incontinence 1261 (880 to 1689) Benefits

18. Archived: Final Research Plan: Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-research-plan/menopausal-hormone-therapy-preventive-medication-december-2017
    October 22, 2015 - Share to Facebook Share to X Share to WhatsApp Share to Email Print archived Final Research Plan Hormone Therapy in Postmenopausal Women: Primary Prevention of Chronic Conditions October 22, 2015 Recommendations made by the USPSTF are indepen…

19. Evidence Summary: Hormone Therapy in Postmenopausal Persons: Primary Prevention of Chronic Conditions | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary28/menopausal-hormone-therapy-preventive-medication
    November 01, 2022 - thromboembolism over 7.2 years (258 vs 181 cases; 77 more [95% CI, 19-153]), and urinary incontinence … thromboembolism (246 vs 126 cases; 120 more [95% CI, 68-185]) over 5.6 years; probable dementia (179 … thromboembolism ( Figure 3 ; strength of evidence reported in Table 2 ). … thromboembolism compared with those who received placebo (77 more cases per 10,000 persons over 7.2 … Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the

20. Medicines to Help Prevent Breast Cancer: Let's Talk About It (pdf file)
    www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/breast-cancer-risk-reduction-discussion-guide.pdf
    September 01, 2019 - difference no difference Fractures Cataracts Endometrial Cancer (cancer of the uterus) Blood Clots (venous … thromboembolism events) * Only tamoxifen is approved for use in premenopausal women. ** Aromatase inhibitors